AstraZeneca plc (LON:AZN) has been assigned a GBX 5,800 ($78.00) price objective by stock analysts at BNP Paribas in a note issued to investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BNP Paribas’ target price would indicate a potential upside of 17.65% from the company’s previous close.

AZN has been the subject of several other research reports. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 4,100 ($55.14) price target on shares of AstraZeneca plc in a report on Monday, September 11th. UBS AG set a GBX 5,150 ($69.26) price target on AstraZeneca plc and gave the company a “neutral” rating in a report on Tuesday, June 27th. Goldman Sachs Group Inc reaffirmed a “sell” rating and set a GBX 3,900 ($52.45) price target on shares of AstraZeneca plc in a report on Thursday, June 1st. Barclays PLC reaffirmed an “overweight” rating and set a GBX 5,500 ($73.96) price target on shares of AstraZeneca plc in a report on Tuesday, August 1st. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a GBX 6,000 ($80.69) price target on shares of AstraZeneca plc in a report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of GBX 5,111.27 ($68.74).

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at

In other news, insider Nazneen Rahman bought 39 shares of the stock in a transaction dated Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($58.77) per share, with a total value of £1,704.30 ($2,291.96).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.